Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
ARCHIVE Sawai Sees 23.48% Reduction in NHI Prices
April 1, 2002
-
ARCHIVE Only 10-20% of Patients with Osteoporosis Receiving Treatment: WLJ Seminar
April 1, 2002
-
ARCHIVE Taiyo to Start Strategy to Promote Use of Generics
April 1, 2002
-
ARCHIVE JACCRO Established to Promote Clinical Trials for Cancer
April 1, 2002
-
ARCHIVE BUSINESS NEWS IN BRIEF
April 1, 2002
-
ARCHIVE RenaScience Offers Renal Disease-Related Genes to Companies
April 1, 2002
-
ARCHIVE Pele Appointed as Japan's Educational Ambassador for ED: Pfizer
April 1, 2002
-
ARCHIVE Utilization of Medicinal Plants Reported by Korosho
April 1, 2002
-
ARCHIVE Our Growth Not Enough for Survival: Mr Yokotsuka of Sumitomo
April 1, 2002
-
ARCHIVE PMS Measures to Be Strengthened in PAL Amendment
April 1, 2002
-
ARCHIVE Kansai Bio Conference in Kobe Focuses on Regenerative Medicine
April 1, 2002
-
ARCHIVE Revision of Medical Fees to Change Outpatients Visiting Pattern
March 25, 2002
-
ARCHIVE Cost Calculation Method Needs Improvements: Dr Sugaya of JMA
March 25, 2002
-
ARCHIVE Operation of Hospitals by Profit-making Organizations Not Recommended
March 25, 2002
-
ARCHIVE RESEARCH & DEVELOPMENT NEWS IN BRIEF
March 25, 2002
-
ARCHIVE Speed of Clinical Trials up to 18 Times Slower in Japan: Korosho
March 25, 2002
-
ARCHIVE Franchise Business GL Proposed by FTC
March 25, 2002
-
ARCHIVE Around 10% Price Reduction to Have Big Impact on Firms
March 25, 2002
-
ARCHIVE NID to Develop Product Information System "Drug Store Navi"
March 25, 2002
-
ARCHIVE Highest Price Reduction Rate Was 78.4%
March 25, 2002
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…